Methamphetamine
| MA | |
|---|---|
| Salts [] | |
|---|---|
| Methamphetamine hydrochloride | |
| Molecular structure via molpic based on CDK |
| Physical properties [] | |
|---|---|
| Molecular mass | 149.23 g/mol [1] |
| Predicted LogP | 2.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C10H15N [1] |
| IUPAC name | N-methyl-1-phenylpropan-2-amine [1] |
| SMILES | CC(CC1=CC=CC=C1)NC [1] |
| InChI | InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3 [1] |
| InChIKey | MYWUZJCMWCOHBA-UHFFFAOYSA-N [1] |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 9 – 12 hours (range 5 – 30 hours); irrespective of route |
| Duration of action | 8 – 12 hours[4] |
| Dosing[] |
|---|
| Insufflated [] | |
|---|---|
| Light | ≤ 15 mg(34x - 41.5%) |
| Common | 15 - 20 mg(13x - 15.9%) |
| Strong | 20 - 27.3 mg(14x - 17.1%) |
| Heavy | 27.3 - 31.8 mg(12x - 14.6%) |
| Extreme | 31.8 mg +(9x - 11%) |
| Intravenous [] | |
|---|---|
| Light | ≤ 56.2 mg(30x - 47.6%) |
| Common | 56.2 - 130 mg(2x - 3.2%) |
| Strong | 130 - 180 mg(22x - 34.9%) |
| Heavy | 180 - 200 mg(6x - 9.5%) |
| Extreme | 200 mg +(3x - 4.8%) |
| Oral [] | |
|---|---|
| Light | ≤ 20 mg(5x - 83.3%) |
| Common | 20 mg |
| Strong | 20 mg |
| Heavy | 20 - 22 mg |
| Extreme | 22 mg +(1x - 16.7%) |
| Intrarectal [] | |
|---|---|
| Light | ≤ 51.2 mg(4x - 57.1%) |
| Common | 51.2 mg |
| Strong | 40 - 200 mg(1x - 14.3%) |
| Heavy | 200 - 300 mg(2x - 28.6%) |
| Extreme | 300 mg + |
| Vaporized [] | |
|---|---|
| Light | ≤ 11.1 mg(12x - 57.1%) |
| Common | 11.1 mg |
| Strong | 10 - 25 mg(4x - 19%) |
| Heavy | 25 - 50 mg(4x - 19%) |
| Extreme | 50 mg +(1x - 4.8%) |
Statistically derived dosages via DBI-IGS We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Methamphetamine (also known as methamphetamine, Methamphetamine, Pervertin, Anadrex, (2-Methylaminopropyl)benzene, Methamphetamine, DL-, N,α-Dimethylbenzeneethanamine, Benzeneethanamine, N,α-dimethyl-, N-Methyl-1-phenyl-2-propylamine or α-Phenyl-β-methylaminopropane) is a stimulant substance of the amphetamine class.
Chemistry
Salts []
Methamphetamine is typically found in the form of its hydrochloride salt.
Stereochemistry []
Methamphetamine is a racemic mixture of the enantiomers.
| Stereoisomerism |
|---|
| Stereoisomer enumberation with rdkit |
Subjective effects []
| x86pup / Methamphetamine [] | |
|---|---|
Routes:
| |
| 0xea / Methamphetamine [] | |
|---|---|
Routes:
| |
Legal status []
- Australia: Methamphetamine is a S8 substance.
- Brazil: Methamphetamine is a F2 substance.[3]
- Canada: Methamphetamine is a Schedule I substance.
- Germany: Methamphetamine is a Anlage II substance.
- New Zealand: Methamphetamine is a Class A substance.
- United Kingdom: Methamphetamine is a Class A substance.
- United States: Methamphetamine is a Schedule I under the "Controlled Substances Act (CSA)".
- European Union: Methamphetamine is a prescription only substance.
- United Nations: Methamphetamine is a Schedule II substance.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 1206, methamphetamine. Accessed April 10, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/1206
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Methamphetamine. UNII: 13ZT6YG5SD. Global Substance Registration System. Accessed April 10, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/13ZT6YG5SD
Anvisa. RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. July 24, 2023. Accessed April 10, 2026. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451
Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. October 1, 2014; 143():11–21.